Omega Therapeutics, Inc. announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders. Mr. Kender?s industry knowledge and proven expertise in corporate finance and business development spanning both large pharmaceutical and emerging biotech companies will be instrumental in supporting the Company?s business objectives. Richard N. Kender is a recognized business leader with an extensive career in the pharmaceutical industry, including 35 years spent at Merck & Co., Inc. During his tenure at Merck, he held various roles across corporate development, including M&A, licensing, financial evaluation and analysis, and global competitive intelligence.

Most recently, he served as Senior Vice President, Business Development and Corporate Licensing from 2000 until his retirement in 2013. Over his career, he has been involved in numerous strategic transactions and played an instrumental role in Merck?s acquisition of Schering Plough. Mr. Kender currently serves on the board of directors of Seres Therapeutics, POXEL SA, Longeveron Inc. and Bicycle Therapeutics.

He received a Bachelor of Science in accounting from Villanova University and a Master of Business Administration from Fairleigh Dickinson University.